A Phase 0 Study of AZD1775 in Preoperative Glioblastoma Multiforme (GBM) Patients Scheduled for Resection to Evaluate for Central Nervous System (CNS) Penetration

Trial Profile

A Phase 0 Study of AZD1775 in Preoperative Glioblastoma Multiforme (GBM) Patients Scheduled for Resection to Evaluate for Central Nervous System (CNS) Penetration

Active, no longer recruiting
Phase of Trial: Phase 0

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs AZD 1175 (Primary)
  • Indications Glioblastoma
  • Focus Pharmacokinetics
  • Most Recent Events

    • 19 Sep 2017 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 10 Jun 2017 Biomarkers information updated
    • 04 Jan 2017 Planned End Date changed from 1 Sep 2017 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top